First Implant of Firehawk® Stent Successfully Completed in Oman

Muscat, Oman [Tuesday 22 September 2020] —On September 10, 2020, the first implant of the Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) developed by Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) was completed successfully in Muscat, Oman.

The surgery was performed at Al-Hayat Hospital by renowned Omani cardiologist Prof. Mohammed El-Deeb, who successfully implanted a 3.5 x 23mm Firehawk® stent. “I am pleased to complete the first implant of Firehawk® after it entered the Omani market,” said Prof. El-Deeb. “The Firehawk® stent has excellent crossability, visibility and radial strength.”

Firehawk® is a drug-eluting stent (DES) with precision target drug-releasing technology and strut in-groove coating. The unique design is made from hair-thin, extremely hard CoCr alloy and includes almost 600 grooves evenly cut throughout. The drug is accurately loaded into the micro grooves via fully automated 3D printing. Firehawk® combines the merits of bare metal stent and DES, allowing it to achieve the same clinical efficacy with significantly lower drug loading.

Firehawk® has been introduced into more than 2,200 hospitals in nearly 40 countries covering key markets across Asia-Pacific, Europe and South America, and is globally recognized by clinical experts for its innovation. The successful implant marks the official entry of Firehawk® into the Omani market, a milestone for MicroPort® in Oman and across the Middle East. MicroPort® is committed to providing high-quality and innovative medical devices and integrated solutions to meet the clinical needs of patients and healthcare experts. As Firehawk® continues to enter new markets, it further strengthens MicroPort®’s cooperation with overseas experts and that ability to provide technologies in the overseas market that benefit patients worldwide.